Logotype for Moberg Pharma

Moberg Pharma (MOB) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Moberg Pharma

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • MOB-015 internationalization advanced with Terclara® launched in Israel, the first market outside the Nordics; preparations with Karo Healthcare progressed toward additional launches.

  • Q3 and 9M revenue increased YoY, while operating and net losses narrowed; cash and cash equivalents were SEK 204.5 million at September 30, 2026.

Financial highlights

  • Q3 net revenue was SEK 5.8 million (4.0); gross profit SEK 3.8 million (2.4); EBIT SEK -3.2 million (-6.0); net loss SEK 1.7 million (4.3).

  • 9M net revenue was SEK 16.5 million (11.5); gross profit SEK 10.8 million (6.7); EBIT SEK -9.8 million (-19.9); net loss SEK 6.3 million (14.5).

  • Diluted EPS was SEK -0.04 in Q3 (-0.09) and SEK -0.13 for 9M (-0.31).

  • Q3 other operating income of SEK 1.8 million (0.1) primarily reflected FX adjustments on USD holdings; exposure was reduced as most holdings shifted to SEK.

Outlook and guidance

  • Karo 2027 launch preparations advanced; first production batches were manufactured, with final batch release pending and initial deliveries expected around year-end.

  • Regulatory, manufacturing and supply planning are progressing in parallel; additional launches are planned over coming years, subject to local approvals.

  • MOB-015 has approvals in 14 countries; partners cover Europe, APAC, Canada, China and Israel, with Karo agreements spanning 19 European markets, four APAC countries and China.

  • A further U.S. clinical study is considered necessary before an FDA application; near-term focus remains approved and partnered markets, while study options and potential partners are evaluated.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Moberg Pharma